Table 5: Clinical characteristics of NMO patients with in relation to the significant HLA alleles and Human promoter TNF alpha polymorphisms.

Variables HLA DRB1
*10:01
HLA DRB1
*11:01 - 11:04
HLA DQA1
*03:01
pTNF-a SNPs
308G/A
(+)
N = 2
(-)
N = 18
(+)
N = 9
(-)
N = 11
(+)
N = 3
(-)
N = 17
A vs. G
F = 0.38 F = 0.77
AO (years)*
P value
29.8 ± 11.3 37 ± 2 27.7 ± 10.3 13.3 ± 4.2 19.0 ± 5.6 11.8 ± 2.8 25.5 ± 13.9 29.7 ± 11.4
P = 0.446 P = 0.47 P = 0.17 P = 0.430
DOD (years)*
P value
6.7 ± 4.4 7.4 ± 2.2 7.2 ± 1.94 7.0 ± 1.05 4.6 ± 0.66 7.47 ± 1.13 8.42 ± 2.43 7.33 ± 1.18
P = 0.316 P = 0.66 P = 0.14 P = 0.783
NR*
P value
3.31 ± 2.10 2.5 ± 0.7 3.44 ± 5.8 3.20 ± 7.85 3.5 ± 1.5 3.29 ± 5.26 2.21 ± 0.78 3.4 ± 0.6
P = 0.84 P = 0.31 P = 0.84 P = 0.891
TM (%)
P value
1 (5) 9 (45) 3 (33.3) 6 (60) 2 (10) 7 (35) 3 (15) 12 (60)
P = 0.526 P = 0.242 P = 0.211 P = 0.15
ON (%)
P value
1 (5) 6 (30) 3 (33.3) 3 (30) 1 (5) 6 (30) 4 (20) 8 (40)
P = 0.684 P = 0.630 P = 0.456 P = 0.88

*: Means ± SD, pTNF-a: TNF alpha polymorphisms; F: Frequencies of alleles A and G; AO: Age at Onset;

DOD: Duration of Disease; NR: Number of Relapses; TM: Transverse Myelitis; ON: Optic Neuritis.